Has Matthias Kapturczak, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,649 in general payments to Matthias Kapturczak, MD across 92 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Matthias Kapturczak, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Matthias Kapturczak, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Matthias Kapturczak, MD

Nephrology · San Antonio, TXNPI 1861429755

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Novo Nordisk at 59.1% of the total. 2025 is the largest year on record at $3,004, 4.0 times the $752 reported in 2019.

$4,649in general payments, 2019–2025

Across 92 payments — averaging $50.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$3K
Veloxis Pharmaceuticals, Inc.$641
Otsuka America Pharmaceutical, Inc.$162
Mallinckrodt Hospital Products Inc.$153
Novartis$149
Celonova Biosciences, Inc.$140
plus $655 from 12 others

$714in research payments, 2019–2025

Across 11 payments — averaging $64.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

CSL Behring$714

What the payments were for

Consulting fees$2,74859%
Food & beverage$1,85240%
Education$491%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	2	$2,748
Veloxis Pharmaceuticals, Inc.	29	$641
Otsuka America Pharmaceutical, Inc.	10	$162
Mallinckrodt Hospital Products Inc.	6	$153
Novartis	5	$149
Celonova Biosciences, Inc.	1	$140
Mallinckrodt Enterprises LLC	9	$135
Amgen(2 entities)	6	$89
AstraZeneca(2 entities)	5	$70
Vifor Pharma, Inc.	4	$68
Takeda Pharmaceuticals U.S.A., Inc.	2	$55
GSK	3	$43
Daiichi Sankyo Inc.	2	$42
Davol Inc.	2	$39
Aurinia Pharma U.S., Inc.	2	$35
Travere Therapeutics, Inc.	2	$33
One Lambda, Inc.	1	$26
AbbVie	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Rivfloza$2,748

How this compares

$4,649 in reported general payments places this provider in the 75th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas →

Medicare billing

Part B allowed, 2024

$40,328

Medicare patients

121

Services billed

415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
TradjentaLinagliptin	15	$10,890
EliquisApixaban	11	$8,725
Valganciclovir Hcl	43	$8,116
Tacrolimus	49	$6,193
XareltoRivaroxaban	11	$3,060
Mycophenolate Mofetil	36	$3,033
Cyclosporine ModifiedCyclosporine, Modified	13	$1,871
Cinacalcet Hcl	17	$1,548
Nano 2nd Gen Pen NeedlePen Needle, Diabetic	17	$1,094
Bumetanide	15	$555
Cefdinir	34	$541
Fludrocortisone Acetate	13	$354
Ondansetron OdtOndansetron	34	$345
Nifedipine ErNifedipine	27	$330
Tamsulosin Hcl	28	$301

Paid to pharmacies, not to this prescriber.

Other nephrology in San Antonio

Luis VelezSan Antonio$505K
Rashid SharafSan Antonio$340K
Carl DukesSan Antonio$238K
Pablo PergolaSan Antonio$164K
Varshasb BroumandSan Antonio$118K
Shweta BansalSan Antonio$89K
Rajeev NarayanSan Antonio$57K
Anwar GergesSan Antonio$50K
Matthew SchaeferSan Antonio$46K
Kumar SharmaSan Antonio$45K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →